Suanfarma Suanfarma

X

Find the latest Drugs in Development and Pipeline Prospector News of Leo Pharma.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Leo Pharma
Denmark Flag
Country
Country
Denmark
Address
Address
Industriparken 55
Telephone
Telephone
+45 4494 5888
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

LP0133 (delgocitinib) cream is an investigational, first-in-class, topical pan-Janus kinase (JAK) inhibitor for CHE. It is under phase 3 clinical development for the treatment of Moderate to Severe Chronic Hand Eczema.


Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LP0133

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 24, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, LEO expand its pipeline by including TMB-001, an investigational topical reformulation of the active pharmaceutical ingredient, isotretinoin that today only exists in an oral formulation in the U.S.


Lead Product(s): Isotretinoin

Therapeutic Area: Dermatology Product Name: TMB-001

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Timber Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition January 23, 2024

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Adbry (tralokinumab-ldrm) is the first treatment for pediatric patients with moderate-to-severe atopic dermatitis specifically targeting the interleukin (IL)-13 cytokine, one of the key drivers of atopic dermatitis signs and symptoms.


Lead Product(s): Tralokinumab-ldrm

Therapeutic Area: Dermatology Product Name: Adbry

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.


Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LP0133

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 30, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LEO 138559 (temtokibart) is an investigational monoclonal antibody that targets the IL-22RA1 receptor subunit, currently in Phase 2 development for the potential treatment of moderate-to-severe atopic dermatitis.


Lead Product(s): Temtokibart

Therapeutic Area: Dermatology Product Name: LEO 138559

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Argenx

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 11, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Through the acquisition, LEO gains rights to establish TMB-001, topical isotretinoin in Timber's patented IPEG™ delivery system, as the standard of care in the treatment of congenital ichthyosis, a devastating, rare disease.


Lead Product(s): Isotretinoin

Therapeutic Area: Genetic Disease Product Name: TMB-001

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Timber Pharmaceuticals

Deal Size: $36.0 million Upfront Cash: $14.0 million

Deal Type: Acquisition August 21, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

LEO Pharma Receives Positive CHMP Opinion for New Adtralza (tralokinumab) Injection Device

Details:

Adtralza (tralokinumab), is a pre-filled pen Injection Device with high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine, which plays a role in the immune and inflammatory processes underlying atopic dermatitis and symptoms.


Lead Product(s): Tralokinumab

Therapeutic Area: Dermatology Product Name: Adtralza

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LEO 138559 is an investigational monoclonal antibody which blocks the IL-22RA1 receptor subunit thereby inhibiting the effect of the interleukin-22 (IL-22) cytokine, it is currently being developed for the treatment of moderate-to-severe atopic dermatitis.


Lead Product(s): LEO 138559

Therapeutic Area: Dermatology Product Name: LEO 138559

Highest Development Status: Phase IIProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

LP0133 (delgocitinib) is a first-in-class investigational topical pan-Janus kinase (JAK)-inhibitor that inhibits activation of the JAK-STAT pathway, which plays a key role in the immune system in driving the pathophysiology of chronic inflammatory skin diseases.


Lead Product(s): Delgocitinib

Therapeutic Area: Dermatology Product Name: LP0133

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Adtralza (tralokinumab), is the first and only approved human, monoclonal antibody developed to specifically target and neutralize the IL-13 cytokine, which plays a key role in immune and inflammatory process which are the underlying causes of atopic dermatitis.


Lead Product(s): Tralokinumab

Therapeutic Area: Dermatology Product Name: Adtralza

Highest Development Status: ApprovedProduct Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 23, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY